MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Zai Lab Ltd ADR

Slēgts

SektorsVeselības aprūpe

32.72 -3.88

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

32.22

Max

34.02

Galvenie mērījumi

By Trading Economics

Ienākumi

33M

-48M

Pārdošana

-2.6M

106M

Peļņas marža

-45.487

Darbinieki

1,869

EBITDA

19M

-56M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+60.5% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 7. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

563M

3.9B

Iepriekšējā atvēršanas cena

36.6

Iepriekšējā slēgšanas cena

32.72

Ziņu noskaņojums

By Acuity

50%

50%

168 / 376 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Zai Lab Ltd ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 10. jūl. 21:42 UTC

Iegādes, apvienošanās, pārņemšana

Justice Department Won't Seek Injunction for T-Mobile Acquisition of U.S. Cellular

2025. g. 10. jūl. 17:06 UTC

Iegādes, apvienošanās, pārņemšana

Portugal Begins Process to Sell Stake in National Carrier -- Update

2025. g. 10. jūl. 17:00 UTC

Galvenie tirgus virzītāji

K Wave Media Shares Drop After Convertible Note Agreement With Anson Funds

2025. g. 10. jūl. 16:31 UTC

Iegādes, apvienošanās, pārņemšana

Blackstone Makes $664 Million Counteroffer for Warehouse REIT Amid Bidding War -- 2nd Update

2025. g. 10. jūl. 23:47 UTC

Tirgus saruna

Gold Edges Higher Amid Lingering Global Trade Tensions -- Market Talk

2025. g. 10. jūl. 23:40 UTC

Tirgus saruna

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2025. g. 10. jūl. 22:36 UTC

Tirgus saruna

Tourism Holdings' Profit Warning Less Concerning Than Others -- Market Talk

2025. g. 10. jūl. 22:23 UTC

Tirgus saruna

New Law Creates Winners and Losers Among Renewable-Energy Projects -- Market Talk

2025. g. 10. jūl. 20:50 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2025. g. 10. jūl. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 10. jūl. 20:00 UTC

Iegādes, apvienošanās, pārņemšana

Toyota Tsusho America Completes Acquisition of Radius Recycling

2025. g. 10. jūl. 19:56 UTC

Tirgus saruna

Gold Rises on Inflation Concerns -- Market Talk

2025. g. 10. jūl. 19:33 UTC

Tirgus saruna

Oil Snaps Winning Streak As Oversupply Concerns Return -- Market Talk

2025. g. 10. jūl. 19:21 UTC

Tirgus saruna

U.S. Natural Gas Rebound on Benign Storage Build -- Market Talk

2025. g. 10. jūl. 18:46 UTC

Tirgus saruna

Mexican Industrial Production Seen as Mixed in May -- Market Talk

2025. g. 10. jūl. 18:15 UTC

Tirgus saruna

Brazil's Bullish Outlook Expected to Survive Trump Tariffs -- Market Talk

2025. g. 10. jūl. 18:03 UTC

Tirgus saruna
Peļņas

Travel Agency Investors Cautiously Optimistic After Delta Report -- Market Talk

2025. g. 10. jūl. 17:57 UTC

Tirgus saruna

US Labor Shortage Could Weigh on Business, Economic Growth -- Market Talk

2025. g. 10. jūl. 17:34 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Conagra Falls While Simply Good Foods Adapts. What's Eating Food Companies. -- Barrons.com

2025. g. 10. jūl. 17:34 UTC

Tirgus saruna

Canada Vows Fight Over Trump's Copper Tariffs -- Market Talk

2025. g. 10. jūl. 17:20 UTC

Tirgus saruna

Copper Climbs as Futures Wrangle With Trump Tariff -- Market Talk

2025. g. 10. jūl. 17:20 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 10. jūl. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 10. jūl. 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 10. jūl. 16:20 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2025. g. 10. jūl. 16:02 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 10. jūl. 16:02 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 10. jūl. 16:02 UTC

Tirgus saruna

Embraer Expected to Bear Brunt of U.S. Tariffs on Brazil -- Market Talk

2025. g. 10. jūl. 16:01 UTC

Iegādes, apvienošanās, pārņemšana

Investor AB: Advanced Instruments' Acquisition of Nova Biomedical Completed

2025. g. 10. jūl. 15:41 UTC

Tirgus saruna

U.S. Natural Gas Storage Surplus Holds Steady -- Market Talk

Salīdzinājums

Cenas izmaiņa

Zai Lab Ltd ADR Prognoze

Cenas mērķis

By TipRanks

60.5% augšup

Prognoze 12 mēnešiem

Vidējais 54.7 USD  60.5%

Augstākais 75 USD

Zemākais 38 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zai Lab Ltd ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

7 ratings

5

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

28.13 / 31.12Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

168 / 376 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.